Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Jun;119(6):4287-4292.
doi: 10.1002/jcb.26687. Epub 2018 Mar 1.

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis

Navid Sobhani  1   2 , Giandomenico Roviello  1   3 , Silvia P Corona  4 , Maurizio Scaltriti  5   6 , Anna Ianza  1 , Marina Bortul  2 , Fabrizio Zanconati  2 , Daniele Generali  1   2
Affiliations
Meta-Analysis

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis

Navid Sobhani et al. J Cell Biochem. 2018 Jun.

Abstract

Breast cancer (BC) is the second most common cause of cancer-related deaths in women worldwide. The availability of reliable biomarkers of response/resistance to cancer treatments would benefit patients and clinicians allowing for a better selection of BC patients most likely to respond to a specific treatment. Phosphatidylinositol 3-kinase (PI3K) enzymes are involved in numerous cellular- functions and processes. The gene encoding for PI3K catalytic subunit p110α is mutated in 20-40% of BC. We performed a meta-analysis of the current literature on randomized clinical trials, investigating the role of PIK3CA mutational status as prognostic factor, and predictor of response to anti-cancer treatments. Overall 1929 cases were included. The pooled analysis confirmed that the presence of a PIK3CA mutation represents an independent negative prognostic factor (HR = 1.67, 95%CI: 1.15-2.43; P = 0.007) in BC, as previously reported. As PI3K signaling is also a result of other pathways' hyperactivation, further investigation of potential biomarkers able to predict likelihood of response to anti-PI3K/mTOR, anti-HER2, and other TKRs is warranted in future randomized clinical trials.

Keywords: PIK3CA; anti-cancer treatment response; breast cancer; meta-analysis; prognostic factor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Forest plots of hazard ratios (HRs) according PIK3CA mutation in breast cancer.
See this image and copyright information in PMC

References

    1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619. - PubMed
    1. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A. 1997;94:4330–5. - PMC - PubMed
    1. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science. 1995;269:690–3. - PubMed
    1. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer. Annu Rev Cell Dev Biol. 2001;17:615–675. - PubMed
    1. Krugmann S, Hawkins PT, Pryer N, Braselmann S. Characterizing the interactions between the two subunits of the p101/p110gamma phosphoinositide 3-kinase and their role in the activation of this enzyme by G beta gamma subunits. J Biol Chem. 1999;274:17152–8. - PubMed

Publication types

MeSH terms

Substances